ClinicalTrials.gg
CompletedNCT03805100XPLOREUpdated Nov 13, 2023Results posted

Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD

A Phase 3 interventional study of Ranibizumab in Macular Degeneration, sponsored by Xbrane Biopharma AB. Completed at 102 sites in 15 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-11-13.

Sponsored by Xbrane Biopharma AB · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
582
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.

Enrollment
13th of 124
582 · median 64
Started
2019
with 1 other
Phase 3
31 of 125
2 open now
Registered
111th of 125
by date

Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 13th largest by enrollment of the 124 interventional ones that give a count, is one of 2 that started in 2019, is one of 31 in phase 3, and was the 111th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing ranibizumab in Macular Degeneration, or all of them as a file.
02

Study summary

The objectives of the study are to demonstrate the equivalence of Xlucane to Lucentis® in treatment of subjects with wet (ie, neovascular) age-related macular degeneration (wAMD).

Read the detailed description

This is a phase III multicenter, double-masked, randomized, parallel group study in subjects with wAMD. Approximately 580 subjects will be enrolled and randomized in a 1:1 ratio to receive either Lucentis® or the investigational product, Xlucane in the study eye once every 4 weeks for 52 weeks. The study eye will be defined as the eye meeting the enrollment criteria. The assigned study drug will be administered as an ophthalmic intravitreal (IVT) injection. A subgroup of 60 subjects at a select number of participating sites will be sequentially asked to participate in an evaluation of PK.

03

Conditions studied

  • Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written and signed form obtained at screening, before any study-related procedures.
  • Willingness and ability to undertake all scheduled visits and assessments as judged by the investigator.
  • Newly diagnosed, active subfoveal Choroidal Neovascularization (CNV) lesion secondary to age-related macular degeneration (AMD) in the study eye. Note: Active CNV indicates the presence of leakage as evidenced by Fluorescein Angiography (FA) and intra- or subretinal fluid as evidenced by Optical Coherence Tomography (OCT) which must be confirmed by the central reading center during Screening:

    1. The area of CNV must be ≥ 50% of the total lesion area in the study eye, and
    2. Total lesion area ≤ 9.0 Disc Areas (DA) in size (including blood, scars and neovascularization) as assessed by FA in the study eye.
  • Best Corrected Visual Acuity (BCVA) of ≤ 73 and ≥ 49 ETDRS letter score in the study eye, using ETDRS chart (20/40 to 20/100 Snellen equivalent) at Screening.
  • Fellow eye should not be expected to need any anti-VEGF treatment for the duration of study participation.
  • Age ≥ 50 years at screening.
  • Male and female subjects of must be willing to completely abstain or agree to use an appropriate method of , from the time of signing informed consent and for the duration of study participation through 3 months, following the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Any previous intervention including pharmacological treatment, laser and/or surgery for wAMD in either eye; (Exception: Vitamin supplementation for AMD prevention).
  • Any previous vitreoretinal surgery in the study eye for any cause.
  • Any previous IVT treatment including any anti-VEGF medications, and/or any other medication in either eye.
  • The use of long-acting steroids, either systemic or intraocular in any eye, in the 18 months before planned initiation of study treatment. (Note: Iluvien® [fluocinolone acetonide intravitreal], current or planned implantation during the study, is prohibited.)
  • Subfoveal fibrosis, atrophy or scarring extending > 50% of total lesion area, in the study eye as assessed by the investigator at screening and confirmed by the central reading center prior to randomization.
  • Choroidal neovascularization in either eye due to non-AMD causes (eg, DME, RVO, ocular histoplasmosis or trauma, etc.) as assessed by FA and confirmed by central reading center.
  • Active or recent (within 28 days prior to randomization) intraocular, extraocular, and periocular inflammation or infection in either eye.
  • History of idiopathic or -associated uveitis in either eye.
  • Infectious conjunctivitis, keratitis, scleritis or endophthalmitis in either eye.
  • Unmedicated intraocular pressure (IOP) ≥ 30 mmHg at Screening in either eye.
  • Topical ocular corticosteroids administered for ≥ 30 consecutive days in the study eye within 90 days prior to Screening.
  • Spherical equivalent of the refractive error in the study eye demonstrating more than 8 diopters of myopia.
  • Corneal transplant or corneal dystrophy in the study eye.
  • History of rhegmatogenous retinal detachment in the study eye.
  • History of macular hole in the study eye.
  • Retinal pigment epithelial tear or rip, involving the macula in the study eye as assessed by FA and confirmed by the central reading center.
  • Current vitreous hemorrhage in the study eye.
  • Subretinal hemorrhage that is ≥ 50% of the total lesion area in the study eye, or if the subretinal hemorrhage involves the fovea is 1 or more DA (≥ 2.54 mm2) in size in the study eye, as assessed by FA and confirmed by the central reading center.
  • Other intraocular surgery (including cataract surgery) in the study eye within the 3 months prior to baseline. The yttrium aluminum garnet [YAG] posterior capsulotomy is allowed not later than 4 weeks prior to screening.
  • Any concurrent intraocular condition in the study eye (eg, cataract or diabetic retinopathy) that, in the opinion of the investigator, could require treatment during the study period to prevent or treat loss of visual acuity.
  • Significant media opacities (including cataract) in the study eye interfering with BCVA assessment or fundus imaging (FA/FP/OCT).
  • Aphakia or absence of the posterior capsule in the study eye, unless it occurred as a result of a YAG posterior capsulotomy in association with prior posterior chamber intraocular lens implantation.
  • Presence of advanced glaucoma or optic neuropathy that involve(s) or threaten(s) the central visual field in the study eye (as judged by the investigator).
  • History of glaucoma filtering surgery or argon laser trabeculoplasty in the study eye (Exception: Laser iridotomy and selective laser trabeculoplasty are allowed).
  • Uncontrolled ocular glaucoma or hypertension in the study eye, defined as IOP ≥ 25 mmHg despite treatment with anti-glaucoma medication.
  • Any previous systemic anti-VEGF treatment (eg, bevacizumab).
  • for Lucentis® ( to ranibizumab or to any of the study treatment ).
  • Current treatment for active systemic infection.
  • Females who are pregnant, nursing, planning a pregnancy during the study, or of and not using a reliable method of and/or not willing to use a reliable method of contraception during their participation in the study.
  • Participation in another clinical trial within the previous 3 months or any other clinical trial of anti-angiogenic drugs.
  • Reasonable suspicion of other disease or condition that might render the subject at a high risk of treatment complications or otherwise confound interpretation of the study results (as judged by the investigator).
  • PK subgroup only: Contraindication for additional blood sampling (as judged by the investigator).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
582 participants (actual)

Study arms

  • Experimental
    Xlucane

    Xlucane (0.05 mL of 10 mg/mL ranibizumab) in the study eye monthly for 52 weeks.

    Biological: Ranibizumab

  • Active comparator
    Lucentis

    Lucentis (0.05 mL of 10 mg/mL ranibizumab) in the study eye monthly for 52 weeks.

    Biological: Ranibizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Best Corrected Visual Acuity (BCVA)

    Change(s) in BCVA letters at Week 8 compared to baseline using the ETDRS protocol

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Change From Baseline in the Total Size of Choroidal Neovascular Leakage Area in the Study Eye

    Change in the total size of choroidal neovascular leakage area in the study eye week 52 compared to baseline measured by Fluorescein Angiography

    Time frame: Baseline and Week 52

  2. Change From Baseline in the Total Size of Choroidal Neovascularisation in the Study Eye

    Change From Baseline in the Total Size of Choroidal Neovascularisation in the Study Eye Measured by Fluorescein Angiography

    Time frame: Baseline and week 52

  3. Central Foveal Thickness in the Study Eye

    Central Foveal Thickness in the Study Eye Measured by Optical Coherence Tomography

    Time frame: Baseline to week 52

  4. Percentage of Subjects With Loss of <15 BCVA Letters

    Percentage of Subjects With Loss of \<15 BCVA Letters Compared to Baseline in the Study Eye

    Time frame: Baseline to week 52

  5. Percentage of Subjects With Gain of ≥15 BCVA Letters

    Percentage of Subjects With Gain of ≥15 BCVA Letters Compared to Baseline in the Study Eye

    Time frame: Baseline to week 52

  6. Subretinal Fluid in the Study Eye

    Change from Baseline in the Amount of Subretinal Fluid in the Study Eye Measured by OCT

    Time frame: Baseline to week 52

  7. Width of Retinal Pigment Epithelium Detachments in the Study Eye

    Change from Baseline in the Width of Retinal Pigment Epithelium Detachments in the Study Eye Measured by OCT

    Time frame: Baseline to Week 52

  8. Pharmacokinetic Plasma Ranibizumab Concentrations

    Pharmacokinetic Plasma Ranibizumab Concentrations (sub-study)

    Time frame: Day 1 to week 20

  9. Height of Retinal Pigment Epithelium Detachments

    Change from Baseline in the Height of Retinal Pigment Epithelium Detachments in the Study Eye Measured by OCT

    Time frame: Baseline to Week 52

07

Results

Posted Nov 13, 2023

Participant flow

Participant flow — Overall Study
MilestoneXlucane (Proposed Ranibizumab Biosimilar)Lucentis (Ranibizumab)
Started292290
Completed245241
Not completed4749

Outcome measures

PrimaryChange in Best Corrected Visual Acuity (BCVA)

Change(s) in BCVA letters at Week 8 compared to baseline using the ETDRS protocol

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · Letters
Change in Best Corrected Visual Acuity (BCVA)
LettersXlucane (Proposed Ranibizumab Biosimilar)Lucentis (Ranibizumab)
Change in Best Corrected Visual Acuity (BCVA)4.57 (3.54 to 5.61)6.37 (5.31 to 7.42)
SecondaryChange From Baseline in the Total Size of Choroidal Neovascular Leakage Area in the Study Eye

Change in the total size of choroidal neovascular leakage area in the study eye week 52 compared to baseline measured by Fluorescein Angiography

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · mm2
Change From Baseline in the Total Size of Choroidal Neovascular Leakage Area in the Study Eye
mm2Xlucane (Proposed Ranibizumab Biosimilar)Lucentis (Ranibizumab)
Change From Baseline in the Total Size of Choroidal Neovascular Leakage Area in the Study Eye-4.09 (-4.66 to -3.52)-3.71 (-4.28 to -3.14)
SecondaryChange From Baseline in the Total Size of Choroidal Neovascularisation in the Study Eye

Change From Baseline in the Total Size of Choroidal Neovascularisation in the Study Eye Measured by Fluorescein Angiography

Time frame:
Baseline and week 52
Reported as:
Least squares mean · mm2
Change From Baseline in the Total Size of Choroidal Neovascularisation in the Study Eye
mm2Xlucane (Proposed Ranibizumab Biosimilar)Lucentis (Ranibizumab)
Change From Baseline in the Total Size of Choroidal Neovascularisation in the Study Eye-1.62 (-2.19 to -1.05)-1.11 (-1.68 to -0.54)
SecondaryCentral Foveal Thickness in the Study Eye

Central Foveal Thickness in the Study Eye Measured by Optical Coherence Tomography

Time frame:
Baseline to week 52
Reported as:
Least squares mean · um
Central Foveal Thickness in the Study Eye
umXlucane (Proposed Ranibizumab Biosimilar)Lucentis (Ranibizumab)
Central Foveal Thickness in the Study Eye-117.44 (-125.33 to 109.55)-115.14 (-123.14 to -107.14)
SecondaryPercentage of Subjects With Loss of <15 BCVA Letters

Percentage of Subjects With Loss of \<15 BCVA Letters Compared to Baseline in the Study Eye

Time frame:
Baseline to week 52
Reported as:
Number · percentage of responders
Percentage of Subjects With Loss of <15 BCVA Letters
percentage of respondersXlucane (Proposed Ranibizumab Biosimilar)Lucentis (Ranibizumab)
Missing at random (MAR)94.896.0
Missing completely at random (MCAR)94.996.1
Missing not at random (MNAR)94.896.1
Composite (Missing and non-evaluable data are classed as no response)68.867.6
SecondaryPercentage of Subjects With Gain of ≥15 BCVA Letters

Percentage of Subjects With Gain of ≥15 BCVA Letters Compared to Baseline in the Study Eye

Time frame:
Baseline to week 52
Reported as:
Number · percentage of responders
Percentage of Subjects With Gain of ≥15 BCVA Letters
percentage of respondersXlucane (Proposed Ranibizumab Biosimilar)Lucentis (Ranibizumab)
Missing at random (MAR)23.629.7
Missing completely at random (MCAR)23.228.8
Missing not at random (MNAR)23.630.4
Composite (Missing and non-evaluable data are classed as no response)17.121.4
SecondarySubretinal Fluid in the Study Eye

Change from Baseline in the Amount of Subretinal Fluid in the Study Eye Measured by OCT

Time frame:
Baseline to week 52
Reported as:
Least squares mean · um
Subretinal Fluid in the Study Eye
umXlucane (Proposed Ranibizumab Biosimilar)Lucentis (Ranibizumab)
Subretinal Fluid in the Study Eye-34.88 (-39.07 to -30.69)-32.93 (-37.21 to -28.65)
SecondaryWidth of Retinal Pigment Epithelium Detachments in the Study Eye

Change from Baseline in the Width of Retinal Pigment Epithelium Detachments in the Study Eye Measured by OCT

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · um
Width of Retinal Pigment Epithelium Detachments in the Study Eye
umXlucane (Proposed Ranibizumab Biosimilar)Lucentis (Ranibizumab)
Width of Retinal Pigment Epithelium Detachments in the Study Eye-161.39 (-387.16 to -135.62)-256.33 (-384.56 to -128.10)
SecondaryPharmacokinetic Plasma Ranibizumab Concentrations

Pharmacokinetic Plasma Ranibizumab Concentrations (sub-study)

Time frame:
Day 1 to week 20
Reported as:
Mean · pg/mL
Pharmacokinetic Plasma Ranibizumab Concentrations
pg/mLXlucane (Proposed Ranibizumab Biosimilar)Lucentis (Ranibizumab)
Day 12230 ± 14292190 ± 1336
Week 202450 ± 13842150 ± 1233
SecondaryHeight of Retinal Pigment Epithelium Detachments

Change from Baseline in the Height of Retinal Pigment Epithelium Detachments in the Study Eye Measured by OCT

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · um
Height of Retinal Pigment Epithelium Detachments
umXlucane (Proposed Ranibizumab Biosimilar)Lucentis (Ranibizumab)
Height of Retinal Pigment Epithelium Detachments-81.49 (-96.33 to -66.66)-73.15 (-88.35 to -57.95)

Adverse events

Collected over From the time the participant signed the written informed consent to 28 days [± 5 days] of receiving last dose of study drug, up to 53 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Xlucane (Proposed Ranibizumab Biosimilar)8/292 (2.7%)33/292 (11.3%)25/292 (8.6%)
Lucentis (Ranibizumab)3/290 (1%)35/290 (12.1%)33/290 (11.4%)
Most frequent serious events
Showing 10 of 74
Most frequent serious events
EventXlucane (Proposed Ranibizumab Biosimilar)Lucentis (Ranibizumab)
COVID-19Infections and infestations5/2921/290
Myocardial infractionCardiac disorders0/2923/290
Urinary tract infectionInfections and infestations3/2920/290
Artrial fibrilationCardiac disorders3/2922/290
Humerus fractureInjury, poisoning and procedural complications3/2920/290
Inguinal herniaGastrointestinal disorders0/2922/290
Pancreatitis acuteGastrointestinal disorders0/2922/290
Transient ischaemic attackNervous system disorders0/2922/290
Retinal pigment epithelial tearEye disorders2/2921/290
PneumoniaInfections and infestations2/2921/290
Most frequent other events
Most frequent other events
EventXlucane (Proposed Ranibizumab Biosimilar)Lucentis (Ranibizumab)
HypertensionVascular disorders10/29217/290
Conjunctival HaemorrhageEye disorders15/29216/290

Baseline characteristics

All 292 subjects in the Xlucane group, and 289 out of the 290 subjects in the Lucentis group were dosed with study drug. 1 subject in the Lucentis group withdrew consent after randomization, and was never treated, therefore was never exposed to study drug.

Age, Categorical
Age, Categorical(Participants)Xlucane (Proposed Ranibizumab Biosimilar)Lucentis (Ranibizumab)Total
<=18 years000
Between 18 and 65 years343266
>=65 years258258516
Age, Continuous
Age, Continuous(Years)Xlucane (Proposed Ranibizumab Biosimilar)Lucentis (Ranibizumab)Total
Mean74.5 ± 8.6873.8 ± 8.2574.1 ± 8.47
Sex: Female, Male
Sex: Female, Male(Participants)Xlucane (Proposed Ranibizumab Biosimilar)Lucentis (Ranibizumab)Total
Female168157325
Male124133257
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Xlucane (Proposed Ranibizumab Biosimilar)Lucentis (Ranibizumab)Total
American Indian or Alaska Native000
Asian444286
Native Hawaiian or Other Pacific Islander000
Black or African American000
White248248496
More than one race000
Unknown or Not Reported000
Best Corrected Visual Acuity
Best Corrected Visual Acuity(Letters)Xlucane (Proposed Ranibizumab Biosimilar)Lucentis (Ranibizumab)Total
Mean61.7 ± 8.1161.5 ± 8.2061.6 ± 8.15
08

Study locations

102 sites
  • Retinal Research Institute, LLC
    Gilbert, Arizona 85296, United States
  • Arizona Retina and Vitreous Consultants
    Phoenix, Arizona 85021-8880, United States
  • Retina Centers P.C
    Tucson, Arizona 85704-5611, United States
  • Win Retina
    Arcadia, California 91006-3607, United States
  • The Retina Partners
    Encino, California 91436-2018, United States
  • Mark B. Kislinger MD Inc.
    Glendora, California 91741, United States
  • Retina Consultants Medical Group Inc.
    Sacramento, California 95819, United States
  • Colorado Retina Associates
    Golden, Colorado 80401-5069, United States
  • Fort Lauderdale Eye Institute
    Fort Lauderdale, Florida 33324-3118, United States
  • Sarasota Retina Institute
    Sarasota, Florida 34239-7246, United States
  • Center for Retina and Macular Disease
    Winter Haven, Florida 33880-3919, United States
  • Southeast Retina Center
    Augusta, Georgia 30909-6440, United States
  • Georgia Retina
    Marietta, Georgia 30060, United States
  • Gailey Eye Clinic
    Bloomington, Illinois 61704, United States
  • Sabates Eye Centers
    Leawood, Kansas 66211, United States
  • Retina Vitreous Surgeons of Central New York PC
    New York, New York 13224, United States
  • Retina Associates of Western New York
    Rochester, New York 14620-4655, United States
  • Charleston Neuroscience Institute
    Ladson, South Carolina 29456, United States
  • Black Hills Regional Eye Institute
    Rapid City, South Dakota 57701, United States
  • Retina Research Institute of Texas
    Abilene, Texas 79606, United States
  • Austin Retina Associates
    Austin, Texas 78705-1169, United States
  • Houston Eye Associates
    Houston, Texas 77025-1756, United States
  • Retina Consultants of Houston
    Houston, Texas 77030-2727, United States
  • Medical Center Ophthalmology Associates
    San Antonio, Texas 78240-1502, United States
  • Retina Consultants of Houston
    The Woodlands, Texas 77384, United States
  • Strategic Clinical Research Group LLC
    Willow Park, Texas 76087, United States
  • Specialized Eye hospital for active treatment Luxor
    Plovdiv, 4000, Bulgaria
  • Specialized eye clinic Zrenie
    Sofia, 1408, Bulgaria
  • Specialized Eye hospital for active treatment Acad. Pashev
    Sofia, 1517, Bulgaria
  • Specialized Hospital for Active Treatment of Eye Diseases "Zora"
    Sofia, 1744, Bulgaria
  • AMCSMP Eye Clinic St. Petka
    Varna, 9010, Bulgaria
  • Všeobecná FN v Praze
    Brno, 625 00, Czechia
  • Oční klinika, Fakultní nemocnice
    Hradec Králové, 50005, Czechia
  • Faculty Hospital Kralovske Vinohrady
    Praha, 10034, Czechia
  • VFN Ocni klinika
    Praha, 12808, Czechia
  • Axon-Clinical, s.r.o.
    Praha, 15000, Czechia
  • Mustame Eye Centre
    Tallinn, 13419, Estonia
  • OÜ Dr Kai Noor Silmakabinet
    Tallin, 11412, Estonia
  • Magyar Honvédség Egészségügyi Központ
    Budapest, 1062, Hungary
  • Department of Ophthalmology, Semmelweis University
    Budapest, 1085, Hungary
  • Bajcsy-Zsilinszky Hospital
    Budapest, 1106, Hungary
  • Szent Imre Teaching Hospital
    Budapest, 1115, Hungary
  • Budapest Retina Associates
    Budapest, 1133, Hungary
  • Jahn Ferenc South-Budapest Hospital
    Budapest, 1204, Hungary
  • University of Debrecen
    Debrecen, 4032, Hungary
  • Szabolcs-Szatmr-Bereg County Hospital
    Nyíregyháza, 4400, Hungary
  • Ganglion Medical Center
    Pécs, 7621, Hungary
  • Markusovszky University Teaching Hospital
    Szombathely, 9700, Hungary
  • Zalan Megyei Szent Rafael kórház
    Zalaegerszeg, 8900, Hungary
  • Rising Retina Clinic
    Ahmedabad, 380015, India
  • Soroka University Medical Center
    Beer Sheva, 84101, Israel
  • Bnai Zion Medical Center
    Haifa, 31048, Israel
  • Rambam Health Care Campus
    Haifa, 3109601, Israel
  • Carmel Medical Center
    Haifa, 3436212, Israel
  • Shaare Zedek Medical Center
    Jerusalem, 9103102, Israel
  • Hadassah University Hospital
    Jerusalem, 9112001, Israel
  • Meir Medical Center
    Kfar Saba, 4428164, Israel
  • Rabin Medical Center
    Petah Tikva, 49100, Israel
  • Kaplan Medical Center
    Reẖovot, 7610001, Israel
  • The Tel Aviv Sourasky Medical Centre
    Tel Aviv, 64239, Israel
  • Asaf Harofe Hospital
    Zrifin, 73000, Israel
  • P.Stradins University Hospital
    Riga, 1002, Latvia
  • The Dr Solomatin Eye Center
    Riga, 1050, Latvia
  • Hospital of Lithuanian University of Health Sciences Kauno klinikos
    Kaunas, 50161, Lithuania
  • Vilnius University Hospital Santaros Klinikos
    Vilnius, 08661, Lithuania
  • Klinika Okulistyczna Oftalmika
    Bydgoszcz, 85631, Poland
  • Professor K. Gibinski University Clinical Centre
    Katowice, 40514, Poland
  • Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie
    Lublin, 20079, Poland
  • Centrum Diagnostyki i Mikrochirurgii Oka LENS
    Olsztyn, 10424, Poland
  • Dr Nowosielska Okulistyka i Chirurgia Oka
    Warszawa, 01249, Poland
  • Retina Okulistyka Sp. z o.o. sp. km
    Warszawa, 01364, Poland
  • Clinica Retina
    Bucharest, 014142, Romania
  • Opticlass Timisoara
    Timişoara, 300012, Romania
  • FGAU NMRC MNTK Eye Microsurgery n.a. acad. S.N. Fyodorov Cheboksary Branch
    Cheboksary, 428028, Russian Federation
  • LLC Kuzlyar
    Kazan, 420066, Russian Federation
  • Federal State Budget Scientific Institute of Eye Diseases
    Moscow, 119021, Russian Federation
  • S. Fyodorov Eye Microsurgery Federal State Institution
    Moscow, 127486, Russian Federation
  • S.Fyodorov Eye Microsurgery Federal State Institution
    Saint Petersburg, 192283, Russian Federation
  • First Pavlov State Medical University of St.Petersburg
    Saint Petersburg, 197022, Russian Federation
  • F.D.Roosevelt Hospital
    Banská Bystrica, 97517, Slovakia
  • Univerzitna nemocnica Bratislava, Nemocnica Ruzinov
    Bratislava, 82606, Slovakia
  • Fakultna nemocnica Trencin
    Trenčín, 91171, Slovakia
  • Fakultna nemocnica s poliklinikou Zilina
    Žilina, 1207, Slovakia
  • Hospital General Universitario de Albacete
    Albacete, 2006, Spain
  • Instituto de Microcirugia Ocular
    Barcelona, 8035, Spain
  • Hospital de Viladecans
    Barcelona, 8840, Spain
  • Bellvitge University Hospital
    L'Hospitalet De Llobregat, 8907, Spain
  • Hospital Universitario Puerta de Hierro-Majadahonda
    Madrid, 02008, Spain
  • Hospital Clinico San Carlos
    Madrid, 28040, Spain
  • Clinica Universidad de Navarr
    Pamplona, 31008, Spain
  • Hospital General de Catalunya
    Sant Cugat Del Vallès, 08195, Spain
  • Hospital Universitario Virgen Macarena
    Sevilla, 41009, Spain
  • Unit of Macula. Oftalvist Clinic
    Valencia, 46004, Spain
  • FISABIO-Oftalmologia Medica FOM
    Valencia, 46015, Spain
  • Hospital Universitario Rio Hortega
    Valladolid, 47012, Spain
  • Hospital Clinico Universitario Lozano Blesa
    Zaragoza, 50009, Spain
  • Hospital Universitario Miguel Servet
    Zaragoza, 50009, Spain
  • Regional Clinical Hospital Center for Emergency Medical Care And Disaster Medicine
    Kharkiv, 61204, Ukraine
  • Medical and Diagnostic Centre PE PMC "Acinus"
    Kropyvnytskyi, 25006, Ukraine
  • Filatov Institute of Eye Diseases Tissue Therapy
    Odessa, 65061, Ukraine

Showing the first 100 of 102 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in May 2021, 24 months.

Results were first posted in Nov 2023, 2 years 6 months after primary completion.

Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 24 months is close to that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2019
First posted
Jan 15, 2019
StartActual
Apr 19, 2019
Primary completionActual
May 11, 2021
CompletionActual
Nov 11, 2021
Results first posted
Nov 13, 2023
Last update
Nov 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03805100
Lead sponsor
Xbrane Biopharma AB
Collaborators
Stada Arzneimittel AG
Responsible party
Sponsor
First posted
Jan 15, 2019
Start date
Apr 19, 2019
Primary completion
May 11, 2021
Completion
Nov 11, 2021
Results posted
Nov 13, 2023
Last update
Nov 13, 2023

Study contacts

Anat Loewenstein, Professor
principal investigator · Tel-Aviv Sourasky Medical Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion